VIDEO: Point-of-care, drug-level assays help predict ‘best time, best dose’ in IBD therapy
Click Here to Manage Email Alerts
DENVER — In a Healio video exclusive, Alan Moss, MD, discusses his presentation at the Crohn’s and Colitis Congress, which detailed the use of therapeutic drug monitoring in the management of patients with inflammatory bowel disease.
Speaking to attendees, Moss, director of the Crohn’s & Colitis program at Boston Medical Center, focused on three areas: the rationale and evidence behind therapeutic drug monitoring (TDM), shifts in understanding how TDM can be applied into practice and evidence supporting using TDM proactively or reactively in patient care, and new innovations in combining pharmacodynamics with pharmacokinetic monitoring to provide a “smarter” version of TDM.
“This incorporates point-of-care assays, assays for drug levels and dashboards that allow you predict the best time and the best dose for your patient’s next infusion or treatment,” Moss said.
Collapse
Moss A. Presentation Sp161: Therapeutic drug monitoring of IBD. Presented at: Crohn’s and Colitis Congress; Jan. 19-21, 2023; Denver (hybrid meeting).
Read more about
Click Here to Manage Email Alerts